• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Kyntra Bio Inc.

    4/27/26 4:07:30 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KYNB alert in real time by email
    DEFA14A 1 kynb-defa14a-2026_na.htm DEFA14A DEFA14A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☑

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☑ Definitive Additional Materials

    ☐ Soliciting Material under §240.14a-12

    Kyntra Bio, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☑ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     


     

    img103820090_0.jpg

    Your Vote Counts! KYNTRA BIO, INC. 2026 Annual Meeting Vote by June 11, 2026 11:59 PM ET [Alt text was not generated.] KYNTRA BIO, INC. 350 BAY ST, STE 100 # 6009 SAN FRANCISCO, CA 94133 V95441-P46761 You invested in KYNTRA BIO, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 12, 2026. Get informed before you vote View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 29, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 12, 2026 8:00 AM Pacific Time Virtually at: www.virtualshareholdermeeting.com/KYNB2026 *Please check the meeting materials for any special requirements for meeting attendance.


     

    img103820090_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Board Recommends Voting Items 1. To elect a Class III director to hold office until the 2029 Annual Meeting of Stockholders. Nominee: 1a. Michael Kauffman, M.D., Ph.D. For 2. To approve, on an advisory basis, the compensation of the Company’s named executive officers. For 3. To ratify the selection, by the Audit Committee of the Board, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2026. For 4. To conduct any other business properly brought before the meeting. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V95442-P46761


    Get the next $KYNB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KYNB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KYNB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Wettig Thane bought $19,852 worth of shares (2,800 units at $7.09), increasing direct ownership by 11% to 27,203 units (SEC Form 4)

    4/A - KYNTRA BIO, INC. (0000921299) (Issuer)

    5/19/26 3:08:15 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane decreased direct ownership by 9% to 27,203 units (SEC Form 4)

    4 - KYNTRA BIO, INC. (0000921299) (Issuer)

    5/18/26 8:00:05 AM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kyntra Bio Inc.

    4 - KYNTRA BIO, INC. (0000921299) (Issuer)

    3/10/26 5:41:32 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KYNB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Wettig Thane bought $19,852 worth of shares (2,800 units at $7.09), increasing direct ownership by 11% to 27,203 units (SEC Form 4)

    4/A - KYNTRA BIO, INC. (0000921299) (Issuer)

    5/19/26 3:08:15 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Wettig Thane decreased direct ownership by 9% to 27,203 units (SEC Form 4)

    4 - KYNTRA BIO, INC. (0000921299) (Issuer)

    5/18/26 8:00:05 AM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KYNB
    SEC Filings

    View All

    SEC Form 10-Q filed by Kyntra Bio Inc.

    10-Q - KYNTRA BIO, INC. (0000921299) (Filer)

    5/12/26 4:05:46 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KYNTRA BIO, INC. (0000921299) (Filer)

    5/11/26 4:05:17 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Kyntra Bio Inc.

    DEFA14A - KYNTRA BIO, INC. (0000921299) (Filer)

    4/27/26 4:07:30 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KYNB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

    Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026 Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug Admi

    5/11/26 4:05:00 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio to Report First Quarter 2026 Financial Results

    SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (NASDAQ:KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone,

    5/4/26 4:05:00 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

    SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB) today announced that the Company will present at the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Monday, April 13, 2026, at 1:30 PM EDT. A live webcast of the presentation will be available here. Kyntra Bio's management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at Needham. A replay of the presentation will be posted, when available, to the Kyntra Bio website on the Events & Presentations page of the Inves

    4/8/26 4:05:00 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KYNB
    Financials

    Live finance-specific insights

    View All

    Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

    Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026 Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC were presented at ASCO GU in February 2026, further validating key Phase 2 monotherapy design elements Pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden is being finalized following feedback from the U.S. Food and Drug Admi

    5/11/26 4:05:00 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio to Report First Quarter 2026 Financial Results

    SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (NASDAQ:KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone,

    5/4/26 4:05:00 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is actively enrolling and remains on track for interim analysis in 2H 2026Positive results from the investigator-sponsored study of FG-3246 in combination with enzalutamide in patients with mCRPC, further validating key Phase 2 monotherapy design elements, were presented at the 2026 ASCO GUSubmitted the pivotal Phase 3 clinical trial protocol for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden to the U.S. Food and Drug AdministrationCash, cash

    3/16/26 4:02:00 PM ET
    $KYNB
    Biotechnology: Pharmaceutical Preparations
    Health Care